Innovate Retina: Challenges of Bringing New Treatments to the Clinic

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Robert Bhisitkul, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: RIBOMIC, Rezolute, Unity Bio, VisgenX. Grant/Research Support: Genentech, NGM Bio, RegenXBio. Stock/Shareholder and Patent: Oculinea.

David Brown, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Alexion, Annexon Biosciences, Apellis, Bayer, Boehringer Ingelheim, Celltrion, ChengduKanhong Biotechnology Co., Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Jefferies, Kodiak, Laboratoires THEA, Lineage, Novartis, Ocular Therapeutix, OPTOS, Regeneron Pharmaceuticals, Retinai Medical, Senju, Stealth, Verseon, and Wedbush. Grant/Research Support: Adverum, Aldeyra, Apellis, Bayer, BIRC, Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation,  F. Hoffmann – La Roche Limited, Gyroscope, Ionis, Iveris, Kodiak, Lowy Medical Research Institute, Lumithera, Nanoscope, NEI/NIH, NGM, Novartis, OIRRC, OPTOS, Oxurion, Regeneron, REGENXBIO, SanChunDang Pharm., Santen, and Senju Pharmaceutical.

Margaret Chang, MD, MS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, and RegnxBio. Grant/Research Support: Allergan, Genentech, Mylan, Novartis, NGM, Opthea, Ophthokol, and Regeneron Pharmaceuticals.

Janet Davis, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: 4DMT, and Kodiak Biosciences. Grant/Research Support: NIH-JHU.

Diana Do, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Boehringer Ingelheim, Kodiak Sciences, Mallinckrodt, Novartis, and Regeneron Pharmaceuticals.  Grant/Research Support: Boehringer Ingelheim, Novartis and Regeneron Pharmaceuticals. Stock/Shareholder: Kodiak Sciences.

David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allegro, Allergan, Apellis, Bausch & Lomb Clearside, Eyepoint, Genentech, Gyroscope, IvericBio, KKR, Kodiak, Novartis, Notal Vision, RecensMedical, Regeneron, and RegenxBio. Grant/Research Support: Alkahest, Alimera, Allergan, Chegdu, Clearside, Gemini, Genentech, Gyroscope, Ionis, IvericBio, Kodiak, Mylan, NGM, Novartis, Ophthotech. Opthea, Recens Medical, and RegenxBio. Speaker’s Bureau: Allergan, Apellis, DORC, EyePoint, Genentech, and Novartis. Stock/Shareholder: Hemera Biosciences, US Retina, Boston Image Reading Center, Clearside, Network Eye.

Jeffrey Heier, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: 4DMT, Abpro, Adverum, Aerie, Affamed, Allegro, Allergan, Allgenesis, Annexon, Apellis, Aprea, Asclepix, Aviceda, BVT, DTx, Eloxx, Galimedix, Genentech/Roche, Graybug, Gyroscope, Horizon Therapeutics, lveric, Kanghong, Lensgen, NGM, Novartis, Ocular Therapeutix, Oriole, Oxurion, Palatin, Regeneron, Regenxbio, Roche, Santen, Scifluor, Stealth Biotherapeutics, Surrozen, Thea, Verseon, Vinci. Grant/Research Support: Apellis, Asclepix, Bayer, Genentech/Roche, Gyroscope, Hemera, lveric, Kanghong, Kodiak, NGM, Notal Vision, Novartis, Regeneron, Regenxbio, and Stealth. Stock/Shareholder: Adverum, Aldeyra, Allegro, Aviceda, Digital Surgery Systems, DTx Pharma, jCyte, Ocular Therapeutix, and Vinci.

Peter Kaiser, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allegro, Allergan, Allgenesis, Alzheon, Annexon Biosciences, AsclepiX, Aviceda, Bayer, Bausch and Lomb, Biogen Idec, Bionic Vision Technologies, Boerenger Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, DelSiTech, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Gemini Therapeutics, Glaukos, Innovent, iRenix, IvericBio, jCyte, Kanaph Therapeutics, Kanghong, Kodiak, LensGen, NGM Biopharmaceuticals, Inc., Novartis, Ocugenix, Oculis, Ocuphire, OcuTerra Therapeutics Inc., Omeros, Opthea, Oxurion, Palatin, Regeneron, RegenxBio, Retinal Sciences, Retrope, Roivant, Samsung Bioepis, Sandoz, Santen, Stealth Biotherapeutics, Sustained Nano Systems, Takeda, Théa, 2020 Onsite.

Arshad Khanani, MD, MA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Allergan, Broadwing Bio, Chengdu, DORC, Genentech, Gyroscope, Gemini Therapeutics, lveric Bio. Kodiak, Nanoscope, Novartis, Opthea, Oxurion, Regenxbio, Roche, 4DMT, Surrozen Kanghong, Recens Medical. Grant/Research Support: Adverum, Allergan, Chengdu Kanghong, Genentech, Gyroscope, Gemini Therapeutics, Kodiak, Novartis, lveric Bio, Neurotech, Opthea, Oxurion, Recens Medical, Roche, Regenxbio. Speaker’s Bureau: Allergan, Genentech, and Novartis.

Prithvi Mruthyunjaya, MD, MHS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Castle Biosciences.

Quong Dong Nguyen, MD, MSc, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Asciepix, Regeneron Pharmaceuticals, Rezolute, and Santen.  Grant/Research Support: Genentech, Gilead, Novartis, Regeneron Pharmaceuticals and Santen.

Carl Regillo MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Adverum, Alderya, Allergan, Annexon, Aviceda, Chengdu Kanghong,  Eyepoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM, Notal, Novartis, Ocugen, Opthea, Stealth, Takeda, and Thea.  Grant/Research: Adverum, Allergan, Annexon, Astellis, Chengdu Kanghong, Eyepoint, Genentech, Graybug, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Opthea, Regeneron, and RegenXBio.

Philip J. Rosenfeld, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Apellis, Bayer, Boehringer-lngelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, Ocunexus (inflammX), Ocudyne, Regeneron, and Unity Biotechnology. Grant/Research Support: Carl Zeiss Meditec, lveric Bio., and Stealth BioTherapeutics. Stock/Shareholder: Apellis. Ocudyne. Valitor, and Verana Health.

Stephen Smith, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Oncopeptides. Stock/Shareholder: iRenix Medical.

Charles Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Adverum, Aerie Pharmaceuticals, Allergan, Allgenesis, Apellis, Arctic Vision, Arrowhead Pharmaceuticals, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, EyePoint Pharmaceuticals, Genentech, Gyroscope, IVERIC Bio, Kato Pharmaceuticals, Kodiak Sciences, Long Bridge Medical, NGM Biopharmaceuticals, Novartis, OccuRx, Ocular Therapeutix, ONL Therapeutics, Opthea Limited, Oxurion, Palatin, PolyPhotonix, RecensMedical, Regeneron, RegenXBio, Roche, SAI MedPartners, Surrozen Takeda, and Verana Health. Grant/Research Support: Adverum, Aerie Pharmaceuticals, Aldeyra, Alimera Sciences, Allergan, Amgen, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Gemini, Genentech, Graybug Vision, Gyroscope, IONIS Pharmaceutical, iRENIX, IVERIC bio, Kodiak Sciences, LMRI, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Oxurion, RecensMedical, Regeneron, RegenXBio, Roche, SamChunDang Pharm, Taiwan Liposome Company, Xbrane BioPharma.

 Paul Yang, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, AGTC, EcoR1, lveric Bio, Nanoscope Therapeutics, ProQR, TeamedOn, Vedere, and 4D.  Grant/Research Support: Acucela, AGTC, Biogen, Editas, FFB, lveric bio, ProQR, Reneuron, Sanofi, Spark, and 4D.

EDITORIAL

The Evolve staff and planners have no financial relationships with commercial interests. iVista staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.